Tenax Therapeutics: Some Future Potential

2026-02-26 14:07:37 ET

Shares of cardiopulmonary concern Tenax Therapeutics, Inc. ( TENX ) have roughly doubled since providing a corporate update and presenting with key opinion leaders on November 13, 2025. The company addressed its rationale for advancing oral levosimendan (TNX-103) against pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). With a pivotal readout expected in 2H26, a PH-HFpEF indication comprising ~1.4 million patients domestically, and no approved therapies, the recent insider buying in Tenax merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: